Stockscreener 앱 받기
32.97
1.43%
-0.48
시장 영업 전:
37.06
4.09
+12.41%
Veracyte Inc 주식(VCYT)의 최신 뉴스
Veracyte Q1 Non-GAAP Earnings, Revenue Rise; Raises 2026 Revenue Guidance; Shares Up Pre-Bell - marketscreener.com
Veracyte Announces First Quarter 2026 Financial Results - BioSpace
Veracyte Q1 Earnings Call Highlights - Yahoo Finance
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Veracyte Inc Earnings Call Signals Profitable Growth - TipRanks
Veracyte Inc (NASDAQ:VCYT) Smashes Q1 Estimates and Raises Full-Year Guidance, Shares Surge - ChartMill
Veracyte (VCYT) Q1 2026 Earnings Transcript - AOL.com
Veracyte Q1 2026 slides: EPS beats by 57%, guidance raised - Investing.com
Full Transcript: Veracyte Q1 2026 Earnings Call - Benzinga
Veracyte: Q1 Earnings Snapshot - kare11.com
Earnings Flash (VCYT) Veracyte, Inc. Reports Q1 Revenue $139.1M, vs. FactSet Est of $130.4M - marketscreener.com
Earnings Flash (VCYT) Veracyte, Inc. Posts Q1 Adjusted EPS $0.52 per Share - marketscreener.com
Cancer test maker Veracyte posts $28.7M profit, raises outlook - Stock Titan
Veracyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Veracyte (NASDAQ: VCYT) boosts Q1 profit and raises 2026 outlook - Stock Titan
Veracyte earnings loom: Investors watch for TrueMRD launch details By Investing.com - Investing.com South Africa
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet - Yahoo! Finance Canada
MSN Money - MSN
Morgan Stanley cuts Veracyte stock price target on valuation methodology - Investing.com
A Look At Veracyte (VCYT) Valuation As New Decipher Bladder And Prostate Data Heads To AUA 2026 - Yahoo Finance
Veracyte Inc (NASDAQ:VCYT) GARP Analysis Reveals Strong Growth at a Reasonable Price - ChartMill
Vanguard reports 5.2% stake in Veracyte (VCYT) via Schedule 13G - Stock Titan
Earnings Preview: Veracyte to Report Financial Results Post-market on May 05 - Moomoo
Will New Decipher Evidence at AUA 2026 Shift Veracyte's (VCYT) Precision Oncology Narrative? - Sahm
Vanguard Portfolio Management (VCYT) reports 4.51M shares, 5.67% stake - Stock Titan
If you invested $1000 in Veracyte a decade ago, this is how much it'd be worth now - MSN
Veracyte Inc (NASDAQ:VCYT): A High-Growth Biotech Stock Poised for a Technical Breakout - ChartMill
Veracyte (VCYT) to Present Extensive Research at AUA 2026 Annual Meeting - GuruFocus
Veracyte (VCYT) to Release Earnings on Tuesday - MarketBeat
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers - Business Wire
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound? - MSN
AEGON ASSET MANAGEMENT UK Plc Has $20.60 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Q3 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Q1 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Q2 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Veracyte Inc at Piper Sandler Healthcare Conference (Virtual)Pre-recorded Fireside Chat Transcript - GuruFocus
Veracyte Inc (VCYT) Stock Up 3.5% and Still Undervalued -- GF Sc - GuruFocus
Veracyte (VCYT) loses 20.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
VCYT Price Today: Veracyte, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Emerging Sub-Segments Transforming the Thyroid Cancer Diagnostics Market Landscape - openPR.com
VCYT Veracyte delivers triple digit Q4 2025 EPS beat and 16 percent annual revenue growth despite mild stock dip.EBITDA Margin - Cổng thông tin điện tử Tỉnh Sơn La
Veracyte (NASDAQ: VCYT) asks investors to back directors, auditor and larger equity plan - Stock Titan
[ARS] VERACYTE, INC. SEC Filing - Stock Titan
Emerging Growth Patterns Driving Expansion in the Liquid Biopsy for Cancer Diagnostics Market - openPR.com
VCYT Maintained by Canaccord Genuity -- Price Target Lowered to $40 - GuruFocus
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Cuts Target Price to $40 - Moomoo
Veracyte Price Target Cut to $40.00/Share From $43.00 by Canaccord Genuity - Moomoo
Veracyte (NASDAQ:VCYT) Given New $40.00 Price Target at Canaccord Genuity Group - MarketBeat
Is Veracyte (VCYT) Offering Value After Mixed Returns And Conflicting Valuation Signals - Yahoo Finance
0.34%
1.63%
자본화:
|
볼륨(24시간):